Skip to Content

EHA24: Severel Advances in the Treatment of Multiple Myeloma

In this MEDtalk, Fredrik Schjesvold, Oslo Myeloma Center, highlights several studies that have and will have great significance for treating multiple myeloma. He is also looking forward to EHA 2024, where he expects positive results from the IMROZ and the BENEFIT studies.

Fredrik Hellem Schjesvold

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top